{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:05:31Z","timestamp":1782486331531,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008867","name":"Department of Education of Zhejiang Province","doi-asserted-by":"publisher","award":["Y201635273"],"award-info":[{"award-number":["Y201635273"]}],"id":[{"id":"10.13039\/501100008867","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Aliskiren is a newly developed drug. Its role in lowering BP has been recognized. However, the role of aliskiren in treating heart and renal diseases are still controversial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To evaluate the existing evidence about clinical efficacy, safety and tolerability of aliskiren monotherapy (AM).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An umbrella review of systematic reviews of interventional studies. We searched Pubmed, Embase and Cochrane Library up to June 2019. Two reviewers applied inclusion criteria to the select potential articles independently. The extract and analyze of accessible data were did by two reviewers independently too. Discrepancies were resolved with discussion or the arbitration of the third author.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eventually, our review identified 14 eligible studies. Results showed that for essential hypertension patients, aliskiren showed a great superiority over placebo in BP reduction, BP response rate and BP control rate. Aliskiren and placebo, ARBs or ACEIs showed no difference in the number or extent of adverse events. For heart failure patients, AM did not reduce BNP levels (SMD -0.08, \u2212\u20090.31 to 0.15) or mortality rate (RR 0.76, 0.32 to 1.80), but it decreased NT-proBNP (SMD -0.12, \u2212\u20090.21 to \u2212\u20090.03) and PRA levels (SMD 0.52, 0.30 to 0.75), increased PRC levels (SMD -0.66, \u2212\u20090.8 to \u2212\u20090.44). For patients who are suffered from hypertension and diabetes and\/or nephropathy or albuminuria at the same time, aliskiren produced no significant effects (RR 0.97, 0.81 to 1.16).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We found solid evidence to support the benefits of aliskiren in the treatment of essential hypertension, aliskiren can produce significant effects in lowering BP and reliable safety. However, the effects of aliskiren in cardiovascular and renal outcomes were insignificant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Study has been registered in PROSPERO (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42019142141\">CRD42019142141<\/jats:ext-link>).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-020-01442-z","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T05:02:24Z","timestamp":1587099744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews"],"prefix":"10.1186","volume":"20","author":[{"given":"Qiyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,17]]},"reference":[{"issue":"6","key":"1442_CR1","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Hypertension. 2018;71(6):e13\u2013e115. https:\/\/doi.org\/10.1161\/HYP.0000000000000065.","journal-title":"Hypertension"},{"issue":"2","key":"1442_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jacc.2017.10.073","volume":"71","author":"P Muntner","year":"2018","unstructured":"Muntner P, Carey RM, Gidding S, Jones DW, Taler SJ, Wright JT Jr, et al. Potential U.S. population impact of the 2017 ACC\/AHA high blood pressure guideline. J Am Coll Cardiol. 2018;71(2):109\u201318. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.073.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1442_CR3","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1161\/CIRCULATIONAHA.114.010676","volume":"130","author":"BM Egan","year":"2014","unstructured":"Egan BM, Li J, Hutchison FN, Ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals. Circulation. 2014;130(19):1692\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.010676.","journal-title":"Circulation"},{"issue":"9859","key":"1442_CR4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/s0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2163\u201396. https:\/\/doi.org\/10.1016\/s0140-6736(12)61729-2.","journal-title":"Lancet"},{"issue":"8","key":"1442_CR5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrd873","volume":"1","author":"MA Zaman","year":"2002","unstructured":"Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov. 2002;1(8):621\u201336. https:\/\/doi.org\/10.1038\/nrd873.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1442_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1084\/jem.106.3.439","volume":"106","author":"LT Skeggs Jr","year":"1957","unstructured":"Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med. 1957;106(3):439\u201353.","journal-title":"J Exp Med"},{"key":"1442_CR7","first-page":"102","volume":"58","author":"MS rao","year":"2010","unstructured":"rao MS. Inhibition of the renin Angiotensin Aldosterone System: focus on Aliskiren. JAPI. 2010;58:102\u20138.","journal-title":"JAPI"},{"key":"1442_CR8","doi-asserted-by":"publisher","first-page":"Cd007066","DOI":"10.1002\/14651858.CD007066.pub3","volume":"4","author":"VM Musini","year":"2017","unstructured":"Musini VM, Lawrence KA, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev. 2017;4:Cd007066. https:\/\/doi.org\/10.1002\/14651858.CD007066.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"jan28 1","key":"1442_CR9","doi-asserted-by":"publisher","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. Bmj. 2013;346(jan28 1):f360. https:\/\/doi.org\/10.1136\/bmj.f360.","journal-title":"Bmj"},{"issue":"3","key":"1442_CR10","doi-asserted-by":"publisher","first-page":"147032031772991","DOI":"10.1177\/1470320317729919","volume":"18","author":"P Nijst","year":"2017","unstructured":"Nijst P, Verbrugge FH, Martens P, Bertrand PB, Dupont M, Francis GS, et al. Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy. J Renin-Angiotensin-Aldosterone Syst. 2017;18(3):1470320317729919. https:\/\/doi.org\/10.1177\/1470320317729919.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"key":"1442_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00041552-199601000-00015","volume":"5","author":"B Braam","year":"1996","unstructured":"Braam B, Koomans H. Renal responses to antagonism of the renin-angiotensin system. Curr Opin Nephrol Hypertens. 1996;5:89\u201396. https:\/\/doi.org\/10.1097\/00041552-199601000-00015.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1442_CR12","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ. 2011;342:d549. https:\/\/doi.org\/10.1136\/bmj.d549.","journal-title":"BMJ"},{"key":"1442_CR13","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"H JPT","year":"2002","unstructured":"JPT H, Thompson SG, JPT H. Thompson SGQuantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1442_CR14","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"issue":"3","key":"1442_CR15","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/hr.2012.185","volume":"36","author":"Y Chen","year":"2013","unstructured":"Chen Y, Meng L, Shao H, Yu F. Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis. Hypertens Res. 2013;36(3):252\u201361. https:\/\/doi.org\/10.1038\/hr.2012.185.","journal-title":"Hypertens Res"},{"issue":"5","key":"1442_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ajh.2011.3","volume":"24","author":"D Gao","year":"2011","unstructured":"Gao D, Ning N, Niu X, Wei J, Sun P, Hao G. Aliskiren vs. angiotensin receptor blockers in hypertension: meta-analysis of randomized controlled trials. Am J Hypertens. 2011;24(5):613\u201321. https:\/\/doi.org\/10.1038\/ajh.2011.3.","journal-title":"Am J Hypertens"},{"issue":"2","key":"1442_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1177\/1470320310381912","volume":"12","author":"Z Zhenfeng","year":"2011","unstructured":"Zhenfeng Z, Huilan S, Junya J, Dong L, Shan L. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension. J Renin-Angiotensin-Aldosterone Syst. 2011;12(2):102\u201312. https:\/\/doi.org\/10.1177\/1470320310381912.","journal-title":"J Renin-Angiotensin-Aldosterone Syst"},{"issue":"6","key":"1442_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2174\/157016110793563924","volume":"8","author":"P Verdecchia","year":"2010","unstructured":"Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol. 2010;8(6):742\u20136.","journal-title":"Curr Vasc Pharmacol"},{"issue":"8 Suppl","key":"1442_CR19","first-page":"S1","volume":"17","author":"B Powers","year":"2011","unstructured":"Powers B, Greene L, Balfe LM. Updates on the treatment of essential hypertension: a summary of AHRQ\u2019s comparative effectiveness review of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and direct renin inhibitors. J Manag Care Pharm. 2011;17(8 Suppl):S1\u201314.","journal-title":"J Manag Care Pharm"},{"issue":"1","key":"1442_CR20","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/hypertensionaha.109.135772","volume":"55","author":"AV Stanton","year":"2010","unstructured":"Stanton AV, Gradman AH, Schmieder RE, Nussberger J, Sarangapani R, Prescott MF. Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials. Hypertension. 2010;55(1):54\u201360. https:\/\/doi.org\/10.1161\/hypertensionaha.109.135772.","journal-title":"Hypertension"},{"key":"1442_CR21","doi-asserted-by":"publisher","unstructured":"Luo Y, Chen Q. Efficacy of aliskiren supplementation for heart failure : a meta-analysis of randomized controlled trials. Herz. 2018. https:\/\/doi.org\/10.1007\/s00059-018-4679-1.","DOI":"10.1007\/s00059-018-4679-1"},{"key":"1442_CR22","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.2147\/dddt.S75111","volume":"9","author":"JT Zhang","year":"2015","unstructured":"Zhang JT, Chen KP, Guan T, Zhang S. Effect of aliskiren on cardiovascular outcomes in patients with prehypertension: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2015;9:1963\u201371. https:\/\/doi.org\/10.2147\/dddt.S75111.","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"1442_CR23","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/1479164117715854","volume":"14","author":"SL Zheng","year":"2017","unstructured":"Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients. Diab Vasc Dis Res. 2017;14(5):400\u20136. https:\/\/doi.org\/10.1177\/1479164117715854.","journal-title":"Diab Vasc Dis Res"},{"issue":"7","key":"1442_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1751-7176.2011.00438.x","volume":"13","author":"WB White","year":"2011","unstructured":"White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients. J Clin Hypertens (Greenwich). 2011;13(7):506\u201316. https:\/\/doi.org\/10.1111\/j.1751-7176.2011.00438.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"2","key":"1442_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2174\/1570161115666170502104809","volume":"16","author":"N Louvis","year":"2018","unstructured":"Louvis N, Coulson J. Renoprotection by direct renin inhibition: a systematic review and Meta- analysis. Curr Vasc Pharmacol. 2018;16(2):157\u201367. https:\/\/doi.org\/10.2174\/1570161115666170502104809.","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"1442_CR26","doi-asserted-by":"publisher","first-page":"140","DOI":"10.2174\/157016112799305094","volume":"10","author":"EC Rizos","year":"2012","unstructured":"Rizos EC, Agouridis AP, Elisaf MS. Aliskiren in patients with diabetes: a systematic review. Curr Vasc Pharmacol. 2012;10(2):140\u20136.","journal-title":"Curr Vasc Pharmacol"},{"issue":"12","key":"1442_CR27","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1097\/HJH.0b013e3283310f92","volume":"27","author":"HJ Lambers Heerspink","year":"2009","unstructured":"Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens. 2009;27(12):2321\u201331. https:\/\/doi.org\/10.1097\/HJH.0b013e3283310f92.","journal-title":"J Hypertens"},{"issue":"1","key":"1442_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.amjmed.2005.08.041","volume":"119","author":"R Latini","year":"2006","unstructured":"Latini R, Masson S, Wong M, Val-HeFT investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med. 2006;119(1):70.","journal-title":"Am J Med"},{"key":"1442_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jcm6060061","volume":"6","author":"ND Pantzaris","year":"2017","unstructured":"Pantzaris ND, Karanikolas E, Tsiotsios K, Velissaris D. Renin Inhibition with Aliskiren: A Decade of Clinical Experience. J Clin Med. 2017;6:6. https:\/\/doi.org\/10.3390\/jcm6060061.","journal-title":"J Clin Med"},{"issue":"16","key":"1442_CR30","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","volume":"374","author":"JJ McMurray","year":"2016","unstructured":"McMurray JJ, Krum H, Abraham WT, Dickstein K, Kober LV, Desai AS, et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in heart failure. N Engl J Med. 2016;374(16):1521\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1514859.","journal-title":"N Engl J Med"},{"issue":"23","key":"1442_CR31","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","volume":"367","author":"HH Parving","year":"2012","unstructured":"Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367(23):2204\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1208799.","journal-title":"N Engl J Med"},{"key":"1442_CR32","doi-asserted-by":"publisher","first-page":"ajpregu.00125.2","DOI":"10.1152\/ajpregu.00125.2017","volume":"313","author":"Y Okada","year":"2017","unstructured":"Okada Y, Shibata S, Fujimoto N, Best S, Levine B, Fu Q. Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients. Am J Phys Regul Integr Comp Phys. 2017;313:ajpregu.00125.2017. https:\/\/doi.org\/10.1152\/ajpregu.00125.2017.","journal-title":"Am J Phys Regul Integr Comp Phys"},{"key":"1442_CR33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00125.2017","volume-title":"Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients","author":"Y Okada","year":"2017","unstructured":"Okada Y, Shibata S, Fujimoto N, Best S, Levine BD, Fu Q. Long-term effects of a renin inhibitor versus a thiazide diuretic on arterial stiffness and left ventricular diastolic function in elderly hypertensive patients; 2017."},{"key":"1442_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/IBPC.S12407","volume":"3","author":"HU Rashid","year":"2010","unstructured":"Rashid HU. Renoprotection, renin inhibition, and blood pressure control: the impact of aliskiren on integrated blood pressure control. Integr Blood Press Control. 2010;3:133\u201344. https:\/\/doi.org\/10.2147\/IBPC.S12407.","journal-title":"Integr Blood Press Control"},{"issue":"4","key":"1442_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.105.063636","volume":"51","author":"TM Coffman","year":"2008","unstructured":"Coffman TM, Crowley SD. Kidney in hypertension: Guyton redux. Hypertension. 2008;51(4):811\u20136. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.105.063636.","journal-title":"Hypertension"},{"key":"1442_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2013.1954","volume":"309","author":"M Gheorghiade","year":"2013","unstructured":"Gheorghiade M, B\u00f6hm M, Greene S, Fonarow G, Lewis E, Zannad F, et al. Effect of Aliskiren on Postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure the ASTRONAUT randomized trial. JAMA. 2013;309:1\u201311. https:\/\/doi.org\/10.1001\/jama.2013.1954.","journal-title":"JAMA"},{"key":"1442_CR37","doi-asserted-by":"publisher","first-page":"f360","DOI":"10.1136\/bmj.f360","volume":"346","author":"H Makani","year":"2013","unstructured":"Makani H, Bangalore S, Desouza K, Shah A, Fh M. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ Br Med J. 2013;346:f360. https:\/\/doi.org\/10.1136\/bmj.f360.","journal-title":"BMJ Br Med J"},{"key":"1442_CR38","volume-title":"Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update","author":"GD Sanders","year":"2011","unstructured":"Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, et al. AHRQ Comparative Effectiveness Reviews. In: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), and Direct Renin Inhibitors for Treating Essential Hypertension: An Update. Rockville: Agency for Healthcare Research and Quality (US); 2011."},{"key":"1442_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/eurjhf\/hfq212","volume":"13","author":"H Krum","year":"2011","unstructured":"Krum H, Massie B, Abraham W, Dickstein K, K\u00f8ber L, McMurray J, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren trial to minimize OutcomeS in patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail. 2011;13:107\u201314. https:\/\/doi.org\/10.1093\/eurjhf\/hfq212.","journal-title":"Eur J Heart Fail"},{"issue":"33","key":"1442_CR40","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339.","journal-title":"Eur Heart J"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-020-01442-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-020-01442-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T23:11:27Z","timestamp":1618614687000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-020-01442-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,17]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1186\/s12872-020-01442-z","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,17]]},"assertion":[{"value":"6 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All our authors report no conflicts of interest in this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"179"}}